Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN


Özgüroğlu M.

Annals of Oncology, vol.1, no.1, pp.1, 2020 (Conference Book)